Possibility of clotting very low after vaccination : Central government panel

New Delhi : Experts investigating serious side effects after corona vaccination have come to know that vaccination decreases the clotting to great extent. Actually the AEFI panel (Adverse Events Following Immunization) was created to examine the side effects of corona vaccination. This panel investigated 498 serious cases and found that only 26 had problems of rare blood clotting. The panel has informed the Ministry of Health on Monday.

The panel said that in Covishield (Oxford-AstraZeneca vaccine), there were 0.61 percent of rare blood clotting cases per 10 lakh cases. The panel has also said that no case of rare blood clotting has come to light in the vaccine cocaine developed by Bharat Biotech and ICMR.

The European Medicines Regulatory body said some time ago that it had found a link between the Oxford-AstraZeneca vaccine and rare blood clotting. However, it has also been said on behalf of the institution that the benefit from the vaccine is so much that the incidents of rare blood clotting can also be ignored. This institution of the European Union denied any ban on the vaccine. But despite this, the news of the link with blood clotting has caused concern among crores of people who have also taken at least one dose of vaccine.

AstraZeneca’s vaccine was being preferred worldwide because of the ease of maintenance compared to the vaccines of Moderna and Pfizer. However, in contrast to Pfizer’s vaccine rate of 95 per cent, the AstraZeneca vaccine has only an efficacy rate of 79 per cent. After the news of blood clotting, there were reports of stopping vaccination from this vaccine in many European countries. South Korea and the Philippines have also stopped the vaccination of the AstraZeneca vaccine.

What is this rare blood clotting
The rare blood clotting, known as ‘Cerebral Venous Sinus Thrombosis (CVST)’, was first caught by the German medical regulator Paul Ehrlich Institute. In mid-March, the institute reported that cases of blood clotting are mostly coming up among young and middle-aged women. After this, Germany stopped using this vaccine among people under 60 years. After Germany’s decision, Canada, Spain, France and Italy took similar steps.